BioCardia, Inc. is a clinical-stage regenerative medicine company specializing in cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company's lead program, CardiAMP, is an autologous mononuclear cell therapy derived from bone marrow that is being developed for ischemic heart failure and chronic myocardial ischemia with refractory angina. CardiAMP is manufactured at the patient's bedside using BioCardia's proprietary cell processing system and delivered via a minimally invasive catheter-based approach. The company also develops CardiALLO and PulmALLO, allogeneic mesenchymal stem cell therapies designed to treat heart failure and acute respiratory distress syndrome. BioCardia provides the Helix biotherapeutic delivery system, a minimally invasive platform enabling targeted delivery of biologic agents to the heart, along with navigation tools like the Morph deflectable guides and Heart3D fusion imaging technology. Headquartered in Sunnyvale, California, BioCardia addresses critical unmet medical needs in cardiovascular and pulmonary disease treatment through its advancing clinical trial programs and innovative delivery technologies.